0 Items - $0.00
A to Z


PKG inhibitor peptide DT-2
Peptide-based inhibitor of protein kinase G
Cat. No.: D 051
CAS No.: [pending]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: D 051-005
Unit: 0.5 mg / ~0.18 µmol
Peptide-based, membrane permeant inhibitor of protein kinase G type Iα and Iβ. Detailed technical information available. Reference: Dostmann et al., Proc. Natl. Acad. Sci. USA, 97, 14772 - 14777 (2000).
Biolog also offers the controlpeptide W45 (Cat. No. W 001).
Cat. No. D 051
CAS number [pending]
Purity > 95% HPLC
Salt form TFA
Storage temperature -20°C / -4°F
Molecular formula C₁₂₂H₂₂₃N₅₃O₂₃
Molecular weight [g/mol] 2800,5
  • 1. Nickl C. K., Raidas S. K., Zhao H., Sausbier M., Ruth P., Tegge W., Brayden J. E.Dostmann W. R. G., Biochim. Biophys. Acta, 1804, 524 - 532 (2010), "(D)-Amino Acid Analogues of DT-2 as Highly Selective and Superior Inhibitors of cGMP-dependent Protein Kinase I alpha"
  • 2. Koika V., Zhou Z., Vasileidis I., Roussos C., Finetti F., Monti M., Morbidelli L.Papapetropoulos A., Vasc. Pharmacol., 53, 215 - 222 (2010), "PKG-I Inhibition Attenuates Vascular Endothelial Growth Factor-stimulated Angiogenesis"
  • 3. Pinkse M. W. H., Rijkers D. T. S., Dostmann W. R.Heck A. J. R., J. Bio. Chem., 284, 16354 - 16368 (2009), "Mode of Action of cGMP-dependent Protein Kinase-specific Inhibitors Probed by Photoaffinity Cross-linking Mass Spectrometry"
  • 4. Lohmann S. M.Walter U., Frontiers Biosci., 10, 1313 - 1328 (2005), "Tracking Functions of cGMP-dependent Protein Kinase"
  • 5. Taylor M. S., Okwuchukwuasanya C., Nickl C. K., Tegge W., Brayden J. E.Dostmann W. R. G., Mol. Pharmacol., 65, 1111 - 1119 (2004), "Inhibition of cGMP-dependent Protein Kinase by the Cell-permeable Peptide DT-2 Reveals a Novel Mechanism of Vasoregulation"
  • 6. Dostmann W. R. G., Tegge W., Frank R., Nickl C. K., Taylor M. S.Brayden J. E., Pharmacol. Ther., 93, 203 - 215 (2002), "Exploring the Mechanisms of Vascular Smooth Muscle Tone with Highly Specific, Membrane-permeable Inhibitors of Cyclic GMP-dependent Protein Kinase I Alpha"
  • 7. Scholten A., Pinkse M. W. H., Maier C. S.Dostmann W. R. G., Abstract of the 13th Protein Kinase Symposium p. 29, 0, 12 - 15 (2002), "Probing Non-covalent Protein-Ligand Interactions of cGMP-dependent Protein Kinase by Nanoflow ESI Orthogonal Time of Flight MS"
  • 8. Dostmann W. R. G., Nickl C. K., Taylor M. S., Brayden J. E., Frank R.Ten Eyck L. F., Cell. Biol. Mol. Lett., 6, 458 - 458 (2001), "Highly Specific and Membrane Permeant Peptide Inhibitors of cGMP-Dependent Protein Kinase I alpha"
  • 9. Dostmann W. R. G., Taylor M. S., Nickl C. K., Brayden J. E., Frank R.Tegge W., Proc. Natl. Acad. Sci. U.S.A., 97, 14772 - 14777 (2000), "Highly Specific, Membrane-permeant Peptide Blockers of cGMP-dependent Protein Kinase I Alpha Inhibit NO-induced Cerebral Dilation"